The Partnership Development Office at Frederick National Laboratory
The National Cancer Institute (NCI) established a partnership initiative in 2008, in response to a nationally recognized need to improve drug development processes and success rates, through enhanced collaboration among government, academia, life sciences companies, and non-profit research organizations. The initiative has culminated in the creation of the Partnership Development Office (PDO) at the Frederick National Laboratory for Cancer Research.
Activities of the PDO include building cross-disciplinary collaborations and teams, bridging the gap between late discovery and early development of diagnostics and therapeutics, developing cross-cutting technology platforms, and developing data standards. The overarching goal is to accelerate treatments for cancer and AIDS patients. The PDO has established numerous partnerships to date.
Many partnerships projects will be accomplished at FNLCR, a Federally Funded Research and Development Center (FFRDC) in Frederick, Md. – a government-owned, contractor-operated laboratory dedicated to biomedical research and development. Opportunities exist to co-locate partnership projects at the Advanced Technology Research Facility (ATRF) (read more).
FNLCR, has a wide range of advanced technologies and innovative platforms that support NCI’s mission, from basic research to translational and clinical studies. These include:
Cancer Model Development Genetics and Genomics Proteins and Proteomics Clinical Assay Development |
Nanotechnology Characterization High-Performance Biomedical Computing Advanced Biomedical Imaging |
For more information please contact:
Bruce Crise Director Business Development SAIC-Frederick, Inc. at FNLCR 301-846-5739 criseb@mail.nih.gov |